KALEIDO BIOSCIENCES INC (KLDO)
US4833471000 - Common Stock
KLDO gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of KLDO have multiple concerns. KLDO is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
KLDO had negative earnings in the past year.
In the past 5 years KLDO always reported negative net income.
In the past 5 years KLDO always reported negative operating cash flow.
1.2 Ratios
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -180.08% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
KLDO does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | -8155.92% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
Compared to 1 year ago, KLDO has more shares outstanding
The debt/assets ratio for KLDO is higher compared to a year ago.
2.2 Solvency
KLDO has an Altman-Z score of -15.43. This is a bad value and indicates that KLDO is not financially healthy and even has some risk of bankruptcy.
KLDO has a Debt/Equity ratio of 0.52. This is a neutral value indicating KLDO is somewhat dependend on debt financing.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.52 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -15.43 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 1.43 indicates that KLDO should not have too much problems paying its short term obligations.
A Quick Ratio of 1.43 indicates that KLDO should not have too much problems paying its short term obligations.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.43 | ||
| Quick Ratio | 1.43 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 11.65% over the past year.
Looking at the last year, KLDO shows a quite strong growth in Revenue. The Revenue has grown by 14.12% in the last year.
EPS 1Y (TTM)11.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.48%
Revenue 1Y (TTM)14.12%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%105%
3.2 Future
The Earnings Per Share is expected to grow by 0.99% on average over the next years.
KLDO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 252.50% yearly.
EPS Next Y10.24%
EPS Next 2Y9.33%
EPS Next 3Y4.15%
EPS Next 5Y0.99%
Revenue Next Year-36.87%
Revenue Next 2Y401.97%
Revenue Next 3Y295.27%
Revenue Next 5Y252.5%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for KLDO. In the last year negative earnings were reported.
Also next year KLDO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 0.05 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.33%
EPS Next 3Y4.15%
5. Dividend
5.1 Amount
No dividends for KLDO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
KALEIDO BIOSCIENCES INC
NASDAQ:KLDO (4/14/2022, 8:00:02 PM)
After market: 0.3003 +0.01 (+3.55%)0.29
-0.01 (-3.69%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners0.01%
Inst Owner Change15.22%
Ins Owners4.76%
Ins Owner Change0%
Market Cap12.36M
Analysts76.67
Price Target11.91 (4006.9%)
Short Float %0.17%
Short Ratio0.01
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 11.17 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.17 | ||
| P/tB | N/A | ||
| EV/EBITDA | 0.05 |
EPS(TTM)-2.16
EYN/A
EPS(NY)-2.07
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.03
BVpS0.25
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -180.08% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | -8155.92% | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.52 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.43 | ||
| Quick Ratio | 1.43 | ||
| Altman-Z | -15.43 |
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)11.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.48%
EPS Next Y10.24%
EPS Next 2Y9.33%
EPS Next 3Y4.15%
EPS Next 5Y0.99%
Revenue 1Y (TTM)14.12%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%105%
Revenue Next Year-36.87%
Revenue Next 2Y401.97%
Revenue Next 3Y295.27%
Revenue Next 5Y252.5%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A